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 2 
ABSTRACT (word count = 250) 19 
We previously demonstrated that for tazobactam administered in combination 20 
with ceftolozane, the pharmacokinetic-pharmacodynamic (PK-PD) index that best 21 
described tazobactam efficacy was the percentage of the dosing interval that 22 
tazobactam concentrations were above a threshold (%T>threshold). Using data 23 
from studies of Enterobacteriaceae-producing ESBL, a relationship between 24 
tazobactam %T>threshold and reduction in log10 CFU from baseline, for which 25 
tazobactam threshold concentration was the product of the isolate’s ceftolozane-26 
tazobactam MIC value and 0.5, was identified. However, since the kinetics of 27 
cephalosporin hydrolysis vary among ESBLs and compounds, it is likely that the 28 
translational relationship to derive the tazobactam threshold concentration varies 29 
among enzymes and compounds. Using a one-compartment in vitro infection 30 
model, the PK-PD of tazobactam administered in combination with cefepime was 31 
characterized and a translational relationship across ESBL-producing 32 
Enterobacteriaceae was developed. Four clinical isolates, two Escherichia coli 33 
and two Klebsiella pneumoniae, known to produce CTX-M-15 β-lactamase 34 
enzymes and displaying cefepime MIC values of 2 to 4 mg/L in the presence of 4 35 
mg/L tazobactam, were evaluated. Tazobactam threshold concentrations from 36 
0.0625-1 times the tazobactam-potentiated cefepime MIC value were 37 
considered. The threshold that best described the relationship between 38 
tazobactam %T>threshold and change in log10 CFU from baseline was the 39 
product of 0.125 and the cefepime-tazobactam MIC (R2=0.813). The magnitude 40 
of %T>threshold associated with net bacterial stasis and a 1-log10 CFU/mL 41 
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 3 
reduction from baseline at 24 hours was 21.9 and 52.8%, respectively. These 42 
data will be useful to support the identification of tazobactam dosing regimens in 43 
combination with cefepime for evaluation in future clinical studies. 44 
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INTRODUCTION 45 
Due to the increasing prevalence of β-lactamase-producing Enterobacteriaceae, 46 
there is renewed interest in β-lactam-β-lactamase inhibitor combinations. This 47 
interest encompasses combinations involving new cephalosporins or inhibitors 48 
and new combinations of old agents. Tazobactam is a penicillanic acid sulfone β-49 
lactamase inhibitor that has been used in combination with piperacillin for over 50 
two decades [1]. Tazobactam was approved by the United States Food and Drug 51 
Administration for clinical use with the anti-pseudomonal cephalosporin 52 
ceftolozane in 2014 [2]. Cefepime-tazobactam combinations, with an 8:1 ratio, 53 
are available from multiple manufacturers in India, but are not licensed elsewhere 54 
[3]. 55 
 56 
Tazobactam extends the spectrum of ceftolozane activity to include many 57 
extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. Like 58 
ceftolozane, cefepime is unstable in the presence of many ESBL enzymes but 59 
has greater inherent stability to Enterobacterial AmpC enzymes [4]. 60 
Administering tazobactam in combination with cefepime increases the agent’s 61 
spectrum of activity to include many ESBL-producing Enterobacteriaceae [5, 6]. 62 
 63 
Recently, we demonstrated that the percentage of the dosing interval that 64 
tazobactam concentrations remained above a threshold (%T>threshold) was the 65 
pharmacokinetic-pharmacodynamic (PK-PD) measure best associated with 66 
efficacy for tazobactam when administered in combination with ceftolozane [7]. 67 
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The tazobactam threshold concentration that allowed co-modeling of 68 
Enterobacteriaceae producing various ESBL enzymes was the product of the 69 
individual isolate’s ceftolozane-tazobactam MIC value and 0.5 [8]. However, 70 
since the kinetics of β-lactam hydrolysis, maximum reaction velocity (Vmax) and 71 
Michaelis-Menten Constant (Km), varies among compounds and enzymes [9], it is 72 
likely that the tazobactam threshold concentration and translational relationships 73 
will vary among cephalosporins. Another source of potential variation is the 74 
permeation rates of the cephalosporin relative to the inhibitor, as cefepime is said 75 
to rapidly permeate cellular membranes [10]. 76 
 77 
Using a one-compartment in vitro infection model, the objectives of this study 78 
were two-fold. The first objective was to confirm  that %T>threshold described 79 
the PK-PD of tazobactam when administered with cefepime. The second 80 
objective was to identify a tazobactam threshold concentration that would allow 81 
co-modeling of isolates and thereby, identify candidate tazobactam dosing 82 
regimens for future combination with cefepime. 83 
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METHODS 84 
Bacteria, antimicrobial, and β-lactamase inhibitor. Cefepime and tazobactam 85 
were obtained from Toronto Research Chemicals (Toronto, Canada) and ACS 86 
Dobfar (Tribiano MI, Italy), respectively. 87 
 88 
The challenge panel of four clinical Enterobacteriaceae isolates with CTX-M-15 89 
ESBLs was obtained from JMI laboratories (North Liberty, Iowa, USA). The panel 90 
was comprised of two Klebsiella pneumoniae and two Escherichia coli isolates 91 
chosen based upon cefepime MIC value when assayed with tazobactam (4 92 
mg/L). 93 
 94 
Media and in vitro susceptibility studies. Susceptibility studies were 95 
conducted in accordance with Clinical and Laboratory Standards Institute 96 
guidelines [11] using cation-adjusted Mueller-Hinton broth (BD laboratories, 97 
Franklin Lakes, New Jersey, USA) in a broth micro-dilution method. Isolate 98 
susceptibility to cefepime was determined alone and in combination with a fixed 99 
tazobactam concentration (4 mg/L). All susceptibility studies were conducted in 100 
triplicate over a 2-day period. 101 
 102 
Whole genome sequencing, epidemiology typing and resistance genes. 103 
Total genomic DNA, extracted using QIAmp genomic DNA kit (Qiagen, Hilden, 104 
Germany), was used to prepare paired end True-Seq library and cluster 105 
generation. Samples were sequenced using Illumina® MiSeq instrument 106 
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 7 
(SeqWright, Houston, TX, USA). Sequences were aligned into multiple contigs 107 
using Lasergene NGen Denovo assembly protocol (DNAStar, Madison, WI). The 108 
ResFinder web server (www.genomicepidemiology.org) was used to identify 109 
acquired antimicrobial resistance genes in the respective assembled genomes, 110 
using a threshold of 98.0% identity. Assembled genomes were also utilized for 111 
determining the multilocus sequence typing (MLST) and analyzing the 112 
sequences of protein membrane genes (OmpC, OmpF and OmpK37), ampC (in 113 
E. coli) and acrA. DNA and protein analysis was performed using the 114 
Lasergene® software package (DNAStar; Madison, Wisconsin). Amino acid 115 
sequences obtained were compared to those of E. coli ATCC 25922 and K. 116 
pneumoniae ATCC 13833. One additional clinical isolate of each species was 117 
also used as control strains and both isolates exhibited a cefepime-tazobactam 118 
MIC results of 1 mg/L. 119 
 120 
Determination of transcription levels of the intrinsic AmpC (E. coli only), 121 
AcrA efflux pump and outer membrane protein genes. The transcription 122 
levels of ampC, acrA, and ompC, ompF and ompK37 were determined by 123 
comparing the transcription levels of these selected targets to those from control 124 
isolates (cefepime-tazobactam MIC, 1 mg/L). Total genomic RNA samples were 125 
extracted from each isolate using the RNeasy Mini Kit in a fully-automated 126 
robotic workstation (Quiacube; Qiagen, Valencia, CA) and residual DNA was 127 
eliminated with RNase-free DNase (Promega, Madison, WI). Sample quality and 128 
quantification of the genomic RNA were assessed using the Agilent 21000 129 
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Bioanalyzer utilizing the RNA 6000 Nano Kit according to manufacturer 130 
instructions (Agilent, Santa Clara, CA). Reverse-transcription PCR was 131 
performed in triplicate using QuantiTect SYBR Green RT-PCR Kit (Qiagen, 132 
Germantown, MD) in the StepOne Plus instrument (Lie Technologies, Foster 133 
City, CA). 134 
 135 
One-comparment in vitro infection model and sample processing. The one-136 
compartment in vitro infection model utilized in these studies has been described 137 
previously [12]. Briefly, the model consists of a central infection compartment 138 
containing growth medium, the challenge isolate and magnetic stir bars to ensure 139 
the homogeneity of drug concentrations and ensure even dispersion of bacteria 140 
within the compartment. This central infection compartment was attached to a stir 141 
plate and the entire unit was placed within a temperature and humidity controlled 142 
incubator set at 35°C. Drug-free growth medium was pumped into the central 143 
infection compartment via a computer-controlled peristaltic pump while growth 144 
medium was simultaneously removed through an exit port and captured in a 145 
waste container. The challenge isolates were aseptically inoculated into the 146 
central infection compartment, and the peristaltic rate of diffusion was set at a 147 
flow rate that allowed for the simulation of human concentration-time profiles for 148 
the drug(s) under study. The test compounds were infused via computer 149 
controlled syringe pumps, allowing simulation of the desired half-lives, dosing 150 
frequencies, and concentrations. Samples for CFU determination and drug 151 
concentration assay were collected from the central infection compartment using 152 
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a sterile syringe and needle through a rubber septum at pre-determined time-153 
points. 154 
 155 
The initial inoculum was 1.0 x 106 CFU/mL of the challenge isolate, prepared 156 
from a culture grown overnight on trypticase soy agar supplemented with 5% 157 
lysed sheep blood (BD Laboratories, Franklin Lakes, New Jersey). Isolates were 158 
taken from these overnight cultures and grown to mid-logarithmic phase in a flask 159 
of Mueller-Hinton broth set in a shaking water bath at 35°C and 125 rotations per 160 
minute. The bacterial concentration was determined by optical density referenced 161 
against previously-confirmed growth curves for each challenge isolate. 162 
 163 
After inoculation into the one-compartment in vitro infection model, bacteria were 164 
exposed to changing concentrations of cefepime and tazobactam simulating 165 
human half-lives of 2 hours for cefepime [13] and 1 hour for tazobactam [14]. 166 
 167 
One milliliter samples were collected for CFU determination at 0, 2, 4, 6, 8, 12, 168 
and 24 hours. Each sample was centrifuged, washed, and re-suspended with 169 
sterile normal saline twice to prevent drug carryover and was then cultured on 170 
trypticase soy agar enriched with 5% sheep blood, as well as Mueller-Hinton 171 
agar infused with cefepime at four times the potentiated MIC value and 172 
tazobactam at a fixed concentration of 4 mg/L. Plated samples were incubated at 173 
35°C for 24 hours and colonies were counted for enumeration of bacterial 174 
density. A few colonies were collected from the drug-containing agar plates to 175 
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survey for any decrease in sensitivity to cefepime-tazobactam. One milliliter 176 
samples were collected from the growth compartment for drug assay at 1, 3, 5, 7, 177 
9, 11, 13, and 24 hours, sterile-filtered, then immediately frozen at -80°C until 178 
assayed for drug concentration. 179 
 180 
Mutation frequency studies. The mutation frequency to drug resistance was 181 
estimated by plating 4 mL of log-phase growth suspension containing an average 182 
concentration of 6.17 x 108 CFU/ml onto agar containing four times the baseline 183 
cefepime MIC value with a fixed 4 mg/L of tazobactam. The bacterial density in 184 
the suspension was determined by quantitative culture, and the ratio of colonies 185 
on the drug-containing plates to that of the starting inoculum provided an 186 
estimate of the drug resistance frequency within a total population. The assay 187 
was performed in duplicate and a subset of isolates from each trial were taken 188 
from the drug-containing plates and re-tested by standard MIC methodology to 189 
confirm decreased susceptibility. 190 
 191 
Dose-ranging studies. Duplicate dose-ranging studies were conducted in order 192 
to determine the dose-response relationship for each challenge isolate. In these 193 
studies, a fixed cefepime dose of either a 1 or 2 g was administered either alone 194 
or in combination with tazobactam, using an every 8 hour (q8h) schedule. The 195 
modelled tazobactam doses ranged from 8 to 4,000 mg following the same q8h 196 
schedule. Both cefepime and tazobactam were administered over a 1 hour 197 
infusion. 198 
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 199 
Analytical method. All samples were assayed by liquid chromatography-tandem 200 
mass spectrometry LC/MS/MS (Waters Xevo TQ-S, Milford MA) and drug levels 201 
were quantitated using external standardization. Standard curves ranged from 202 
0.500 to 200 mg/L for cefepime and from 0.0100 to 20.0 mg/L for tazobactam. 203 
The standard curves were linear over their respective ranges (r2=0.974 and 204 
0.988 or greater) for cefepime and tazobactam, respectively. The lower limit of 205 
quantification was 0.500 mg/L for cefepime and 0.0100 mg/L for tazobactam. The 206 
intra-assay percent coefficient of variation (%CV) for cefepime quality control 207 
samples at concentrations of 5.0, 25.0, and 100 mg/L was 15.2% or less. The 208 
intra-assay %CV for tazobactam quality control samples at concentrations of 209 
0.05, 0.5, and 5.0 mg/L was 7.04% or less. Inter-assay %CVs for the cefepime 210 
quality control samples at concentrations of 5.00, 25.0, and 100 mg/L were 211 
8.70% or less and 5.83 % or less for tazobactam quality control samples at 212 
0.0500, 0.500, and 5.00 mg/L. Diluted quality control samples for tazobactam 213 
(100 mg/L) exhibited a inter-assay %CV of 5.24% or less and an intra-assay 214 
%CV of 6.19% or less in runs which required dilution of samples into the 215 
calibration curve range. 216 
 217 
Pharmacokinetic-pharmacodynamic analysis. Data from the dose-ranging 218 
studies were evaluated using Hill-type models and non-linear least squares 219 
regression. The data were weighted using the inverse of the estimated 220 
measurement variance. Relationships between change in log10
 
CFU at 24 hours 221 
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and tazobactam %T>threshold were evaluated. Tazobactam %T>threshold was 222 
identified through an iterative process in which candidate tazobactam threshold 223 
concentrations, representing the product of the tazobactam-potentiated cefepime 224 
MIC value and 1, 0.5, 0.25, 0.125, and 0.0625 for each individual isolate, were 225 
evaluated. Discrimination among tazobactam threshold concentrations was 226 
based on the evaluation of the dispersion of data along the %T>threshold axis 227 
and optimization of r2 values for the relationship between change in log10 CFU at 228 
24 hours and tazobactam %T>threshold. 229 
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RESULTS 230 
In vitro susceptibility testing, whole genome sequencing, epidemiology typing and 231 
determination of transcription levels of intrinsic AmpC, AcrA, and outer 232 
membrane protein levels. Table 1 shows the β-lactamase enzyme(s) identified 233 
within the challenge panel and the MIC values for cefepime and tazobactam 234 
alone and combined with 4 mg/L of tazobactam. All four isolates carried CTX-M-235 
15, and it was the sole enzyme in E. coli 30854. The remaining isolates produced 236 
additional enzymes including OXA-1/30, TEM-1 and SHV-1 and -28. MIC values 237 
≥ 256 mg/L for tazobactam and ≥ 32 mg/L for cefepime alone were recorded for 238 
all four isolates. When cefepime was studied in combination with 4 mg/L 239 
tazobactam, the MIC values of the isolate panel ranged from 2 to 4 mg/L, 240 
representing the high end of the susceptible range for cefepime against 241 
Enterobacteriaceae [11].  242 
 243 
An array of resistance determinants were detected, especially in isolates 39930 244 
and 25021 as shown in Table 1. Higher expression levels of OmpC (47- to 62-245 
fold more than the control strain) were observed in both E. coli. Moreover, E. coli 246 
30854 also expressed the intrinsic AmpC gene 17-fold more than the control 247 
strain. In addition, K. pneumoniae 604 and 25021 showed lower expression 248 
levels (approximately a third) of OmpK37 when compared with that of a control 249 
strain.  250 
 251 
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Sequence analysis of genes of interest demonstrated that all isolates included in 252 
the study had several alterations in the OmpK36 (OmpC analogue of E. coli)-253 
encoding gene. Several alteration, deletions and insertions were noted, including 254 
an insertion in the L5 region of OmpC in both E. coli, and mutations and six 255 
amino acid deletions in L5 and L6, respectively in both K. pneumoniae isolates. 256 
Other genes investigated (ampC, acrA, OmpF and OmpK37) showed sequences 257 
similar to the control isolates. 258 
 259 
Pharmacokinetics. The targeted cefepime and tazobactam pharmacokinetic 260 
profiles were well-simulated in the in vitro infection model for all studied dosing 261 
regimens. Figure 1 shows the relationship between observed and targeted drug 262 
concentrations. As evidenced by the high coefficient of determination values 263 
(cefepime, R2=0.967; tazobactam, R2=0.991), there was excellent precision but 264 
with a modest tendency to underpredict concentrations, as evidenced by the 265 
slope values (cefepime, 14.18%; tazobactam, 13.53%).  266 
 267 
Drug concentrations for cefepime and tazobactam were each fit to a one-268 
compartment model with zero-order input and first-order elimination.  The 269 
pharmacokinetic data for each agent were well described by this model. 270 
 271 
Mutation frequency studies. The mean densities the of drug-resistant 272 
subpopulation observed at four times the baseline cefepime-tazobactam MIC for 273 
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 15 
each challenge isolate are presented in Table 2; these frequencies ranged from 274 
1.3 x 10-7 to 3.5 x 10-8 CFU. 275 
 276 
Dose-ranging studies. Bacteria in the no-treatment control arms grew well in 277 
each case, reaching a density exceeding 1.0 x 108 CFU/mL by 12 hours (Figure 278 
2 A-D).The cefepime and tazobactam monotherapy control regimens behaved as 279 
expected: i.e., the tazobactam arms performed similarly to the no-treatment 280 
control arms and the cefepime arms provided some initial cell kill but with full 281 
regrowth by 24 hours. 282 
 283 
The range of tazobactam doses used in combination with the fixed cefepime 284 
dosing regimens provided a full spectrum of drug effects for each challenge 285 
isolate. For example, the low-intensity cefepime (1 g)-tazobactam (8 mg) regimen 286 
behaved similarly to cefepime (1 g) alone while intermediate-intensity cefepime 287 
(1 g)-tazobactam (15.6 to 125 mg) dosing regimens resulted in net bacterial 288 
stasis at the 24 hour time point (Figure 2A) and the, high-intensity cefepime (1 289 
g)-tazobactam (250-500 mg) regimens achieved slightly more than a 1 log10 290 
CFU/mL reduction from baseline (Figure 2A). 291 
 292 
Drug-resistant isolates were observed for all controls, including the cefepime and 293 
tazobactam monotherapy dosing regimens. Drug-resistant isolates were also 294 
observed for three of the cefepime-tazobactam dosing regimens and typically 295 
occurred in low-intensity tazobactam regimens (8 to 250 mg) (Figure 2 A-D). The 296 
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MIC values of the isolates collected from the drug-containing plates from the 297 
mutation frequency studies and dose-ranging studies were determined and are 298 
presented in Table 2. 299 
 300 
Pharmacokinetic-pharmacodynamic analysis. The relationships between 301 
change in log10 CFU over 24h and the tazobactam %T>threshold for tazobactam 302 
threshold concentrations from 0.0625- to 1-times the cefepime-tazobactam MIC 303 
are presented in Figure 3. The coefficient of determination (r2) and scatter of 304 
data about the fitted function across the X-axis were most optimal for the Hill 305 
functions describing the relationships between the change in log10 CFU/mL from 306 
baseline and the product of the cefepime-tazobactam MIC and either 0.0625 or 307 
0.125. Emphasis was placed on a tazobactam threshold concentration of 0.125 308 
times the cefepime-tazobactam MIC. The basis for the focus on this threshold 309 
was  the modestly better scatter of data across the range of tazobactam 310 
%T>thresholds than that based on the data using the tazobactam threshold 311 
concentration of 0.0625 times the MIC, without less apparent clustering of data 312 
points at the lower (0) and upper (100) margins of the range. The %T>thresholds 313 
based on the tazobactam threshold concentration of 0.125 times the cefepime-314 
tazobactam MIC associated with net bacterial stasis and a 1-log10 CFU reduction 315 
in bacterial burden at 24 hours were 21.9 and 52.8%, respectively. The 316 
parameter estimates (standard errors) for the relationship between change in 317 
log10 CFU and tazobactam %T>threshold were E0 2.69 (0.22), Emax 12 (38.3), 318 
Hill’s constant 0.48 (0.65), and EC50 277.51 (3241.81). 319 
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Discussion 320 
The objectives of these studies were two-fold. The first was to use a one-321 
compartment in vitro infection model to confirm that %T>threshold described the 322 
PK-PD of tazobactam when administered in combination with cefepime. The 323 
second was to identify a tazobactam threshold concentration that would allow co-324 
modeling across isolates, and using this, %T>threshold targets that could be 325 
used to identify candidate tazobactam dosing regimens in combination with 326 
cefepime for future study. 327 
 328 
We confirmed that the PK-PD index associated with efficacy for tazobactam 329 
against Enterobacteriaceae was %T>threshold when tazobactam administered in 330 
combination with cefepime. These findings are consistent with those for 331 
tazobactam paired with ceftolozane [3]. The two tazobactam threshold 332 
concentrations that allowed the entire challenge panel to be co-modeled with the 333 
most optimal fit of the model to the data were those based on the product of the 334 
cefepime-tazobactam MIC and either 0.0625 or 0.125. For reasons described 335 
above, 0.125 x cefepime-tazobactam MIC was considered the more optimal 336 
threshold. This multiple is significantly lower than the 0.5 x MIC previously 337 
identified for ceftolozane-tazobactam [8]. Moreover, the %T>threshold 338 
tazobactam concentration associated with net bacterial stasis and a 1-log10 CFU 339 
reduction from baseline were lower for cefepime-tazobactam (net bacterial stasis, 340 
21.9; 1 log10 CFU reduction from baseline, 52.8) than for ceftolozane-tazobactam 341 
(net bacterial stasis, 65.9; 1-log10 CFU reduction from baseline, 77.3) [8]. The 342 
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tazobactam doses administered q8h that correspond to the % T > MIC*0.125 343 
required to achieve net bacterial stasis and a 1-log10 CFU reduction from 344 
baseline were 31.25 to 62.5 mg and 125 to 250 mg, respectively, for isolates with 345 
potentiated MICs of 2 and 4 mg/L. It is worthwhile to note that one isolate, 346 
K. pneumoniae 604, was common to the studies described herein and those 347 
previously-conducted for ceftolozane-tazobactam [8].  348 
 349 
When the results of both sets of evaluations are considered, these data imply 350 
that a lower tazobactam exposure was required for a given level of drug effect 351 
when tazobactam was combined with cefepime rather than ceftolozane. Possible 352 
explanations, which are not mutually exclusive, are that cefepime and 353 
ceftolozane may differ in the following ways: (i) in their lability to the ESBLs 354 
represented; (ii) in their affinity for these enzymes, which determines the extent 355 
to which they may outcompete the inhibitor for enzyme binding; and (iii) in their 356 
relative acylation and deacylation rates, which may determine the extent that the 357 
enzyme is held in a form invulnerable to attack by tazobactam or relative 358 
permeation rate into the bacterial periplasm. 359 
 360 
There are two limitations of the studies described herein that deserve comment.  361 
The first limitation is that the one-compartment in vitro infection model utilized for 362 
these studies does not account for the effect of an immune system and is 363 
conducted using Mueller-Hinton broth media that optimizes bacterial growth. The 364 
impact of the former is that the magnitude of the %T>threshold for tazobactam 365 
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may be overestimated. The second limitation is that the duration of the studies 366 
carried out was 24 hours. This duration of the study was insufficient to evaluate 367 
the effect of intensity and duration of therapy of each tazobactam dosing regimen 368 
on the amplification of pre-existing drug-resistant bacterial subpopulations.  The 369 
impact of the limited duration of the experiment is that the magnitude of the 370 
%T>threshold for tazobactam may in fact be underestimated. Additional studies 371 
utilizing immunocompetent and immunosuppressed animal infection and hollow-372 
fiber in vitro infection models will be needed to address these limitations. 373 
 374 
In conclusion, we confirmed that the PK-PD index associated with tazobactam 375 
efficacy when administered in combination with cefepime was %T>threshold. 376 
This finding was consistent with the PK-PD index associated with tazobactam 377 
efficacy when administered in combination with ceftolozane. Through this 378 
evaluation, we also identified a tazobactam threshold concentration, which was 379 
the product of the cefepime-tazobactam potentiated MIC and 0.125. The use of 380 
this threshold allowed for data from the entire challenge panel to be co-modeled 381 
with the most optimal fit of the model to the data. These data will be useful to 382 
identify candidate tazobactam dosing regimens to be administered in 383 
combination with cefepime for future study. 384 
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Table 1.  Susceptibility testing results, identified β-lactamase enzymes, and transcription levels of outer membrane 
proteins and AmpC expression for the Enterobacteriaceae panel 
Isolate 
Identified  
β-lactamase  
enzyme(s) 
Omp transcription  
level
a
 
AmpC  
transcription  
levela 
Microbroth MIC values
b
 
(mg/L) 
TAZ  
alone 
FEP 
alone 
FEP-TAZ 
(4 mg/L) 
E. coli  
30854 
CTX-M-15 OmpC (47) AmpC (17) 512 256 2 
E. coli  
39930 
CTX-M-15, TEM-1,  
OXA-1/30, SHV-28 
OmpC (62) AmpC (1) 256 128 4 
K. pneumoniae 
25021 
CTX-M-15, TEM-1,  
OXA-2 
OmpK (-33) ND 512 32 4 
K. pneumoniae 
604 
CTX-M-15, OXA-1/30,  
SHV-1 
OmpK (-33) ND 512 >512 4 
a. Represented as fold increases from that of control isolates which had tazobactam-potentiated cefepime MIC values of 1 mg/L using a 
fixed 4 mg/L concentration of tazobactam.  
b. All MIC values shown represent modal values. 
Omp=Outer membrane protein; FEP=Cefepime; TAZ=Tazobactam; ND = Not Determined 
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Table 2. Mutation frequencies and MIC values for mutants collected from the drug-containing plates utilized in the 471 
dose-ranging efficacy and mutation frequency studies 472 
Isolate 
Baseline 
cefepime- 
tazobactam MICa 
Geometric mean of 
cefepime-tazobactam  
mutation frequency  
Cefepime/ tazobactam 
MIC for isolates taken 
from drug-containing 
platea 
E. coli 30854 2 1.3 x 10-7  8 to 32  
E. coli 39930 4 9.4 x 10-7 32 to 64 
K. pneumoniae 25021 4 1.8 x 10-7   16 to 128 
K. pneumoniae 604 4 3.5 x 10-8  8 
a. All MIC values shown, as mg/L, represent modal values determined using broth microdilution and tazobactam at a fixed 
4 mg/L concentration. 
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Figure 1. The relationships between the observed and targeted PK profiles simulated over the 24 hour in vitro 473 
experiment for cefepime (A) and tazobactam (B) 474 
 475 
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Figure 2. Averaged dose-ranging study results for the four Enterobacteriaceae isolates examined (A. E. coli 30854, B. 476 
E. coli 39930, C. K. pneumoniae 25021, D. K. pneumoniae 604). The data series with black outlines represent regimens 477 
found to contain a drug-resistant sub-population on or before the 24-hour time point. FEP=Cefepime, TAZ=tazobactam.478 
 479 
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 Figure 3. Relationship between change in log10 CFU after 24 hours of exposure and tazobactam %T>threshold based 480 
on data from a one-compartment in vitro infection model. The tazobactam threshold concentrations evaluated represent 481 
the product of each individual isolates cefepime-tazobactam MIC and either 1, 0.5, 0.25, or 0.125. Different colors 482 
represent each of the four different isolates examined 483 
 484 
 o
n
 O
ctober 2, 2017 by University of East Anglia
http://aac.asm
.org/
D
ow
nloaded from
 
